Publication
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMultiple Myelomacivic_curation1.00
- drugLetetresgene Autoleucelcivic_curation1.00
- geneCTAG1Bcivic_curation1.00
- geneCTAG2civic_curation1.00
- variantCTAG1B Overexpressioncivic_curation1.00
- variantCTAG2 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26193344
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CTAG1B Overexpression1 | ||||||||
| Letetresgene Autoleucel | Multiple Myeloma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2940Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing … (full text at CIViC) PMID 26193344 · Rapoport et al., 2015 · Open in CIViC | civic |
| CTAG2 Overexpression1 | ||||||||
| Letetresgene Autoleucel | Multiple Myeloma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID2941Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing … (full text at CIViC) PMID 26193344 · Rapoport et al., 2015 · Open in CIViC | civic |